The US Food and Drug Administration has approved pivmecillinam (Pivya) tablets to treat uncomplicated urinary tract infections in women.
The beta-lactam antibiotic already is approved in Europe and has been used for more than 40 years outside of the United States to treat infections, according to the drug's manufacturer, Utility Therapeutics. , which is marketing the medication as Pivya. Escherichia coli, Proteus mirabilis,Researchers studied the treatment in three clinical trials .
One study found women who received the new antibiotic were more likely to have resolution of symptoms and a reduction in bacteria in urine compared with placebo . Similar results were seen in a trial that usedIn a third study that assessed two oral antibacterial drugs, 72% of women who received pivmecillinam and 76% who received the other drug achieved resolution of symptoms and a reduction in bacteria, according to the FDA.
UTI - Urinary Tract Infection UTI Antibiotics Bacteria Bacterial Infection Proteus Infection Staphylococcal Infections Staph Infection Staphylococcus Infection Adverse Effects Side Effects Antibacterial Bacteriocide Bactericide Clinical Research Clinical Trials Clinical Studies Pre-Clinical Trial Double-Blind Study Double-Blind Studies Single-Blind Study
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves Basilea Pharmaceutica's Antibiotic for Multidrug-Resistant Bacterial InfectionsThe U.S. health regulator approved Basilea Pharmaceutica's antibiotic for bacterial infections including multidrug-resistant strains, expanding treatment options for patients. The antibiotic, ceftobiprole, will be sold under the brand name Zevtera in the U.S.
Read more »
FDA Approved New Antibiotic Against UTIsAs many patients already know, urinary tract infections (UTIs) can recur despite the use of antibiotics. So, it's welcome news that the U.S. Food and Drug Administration on Wednesday approved Pivya (pivmecillinam) to fight bacterial UTIs. 'UTIs are a very common condition...
Read more »
FDA Approves New Bladder Cancer DrugThe first-in-class agent is approved alongside bacillus Calmette-Guérin to treat certain non–muscle-invasive bladder cancers that do not respond to bacillus Calmette-Guérin alone.
Read more »
Antibiotic Recalled Over 'Super Potent' Dosage—Serious Side Effects Possible, FDA WarnsDigital destination for sophisticated men & women. Live your best life with expert tips and news on health, food, sex, relationships, fashion and lifestyle.
Read more »
FDA Approves Danicopan as Add-On Therapy for Hemolysis TreatmentThe US Food and Drug Administration has approved danicopan (Voydeya, AstraZeneca) as an add-on therapy to treat extravascular hemolysis in adults receiving ravulizumab orPNH is a rare blood disorder affecting 1-10 individuals per million. The condition, which eliminates red blood cells and leads to blood clots and impaired bone marrow function, can cause life-threateningRavulizumab and eculizumab, also both made by AstraZeneca, inhibit the destruction of red blood cells. However, 10%-20% of patients treated with the antibody infusions experience significant extravascular hemolysis, in which these surviving red blood cells are eliminated by the spleen and liver. Extravascular hemolysis can lead to ongoing anemia, which can lead patients to require blood transfusions. Danicopan, an investigational, first-in-class, oral complement factor D inhibitor, is designed to control intravascular hemolysis and prevent extravascular hemolysis
Read more »
FDA Approves TriClip for Tricuspid RegurgitationThe FDA has approved the use of TriClip for the treatment of tricuspid regurgitation. The decision was based on the results of a randomized controlled trial, which showed that patients who underwent repair with the TriClip system experienced a significant reduction in valve dysfunction and improvement in quality of life. The procedure was found to be safe, with a low rate of major adverse events.
Read more »